To our knowledge, RAF dimerization studies evaluating pan-RAF inhibitors in various BRAF-mutant cancer cells have not been reported; beyond demonstrating MOA, we aimed to also address this knowledge gap. The gene discussed is RAF1; the disease is cancer.